- Home
- ZLAB
ZLAB
Zai Lab Limited
as 11-14-2024 4:00pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 3.0B | IPO Year: | 2017 |
| Target Price: | $52.50 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.48 - $36.60 | Next Earning Date: | 11-12-2024 |
| Revenue: | $355,748,000 | Revenue Growth: | 35.01% |
| Revenue Growth (this year): | 48.5% | Revenue Growth (next year): | 47.37% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chen Yajing | ZLAB | Chief Financial Officer | Nov 1 '24 | Sell | $30.66 | 167 | $5,120.55 | 15,494 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Oct 1 '24 | Sell | $25.40 | 301 | $7,644.80 | 15,494 | |
| GAYNOR RICHARD | ZLAB | Director | Sep 3 '24 | Sell | $19.50 | 2,500 | $48,750.00 | 46,568 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 hours ago
Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations
MT Newswires
a day ago
Zai Lab Launches $200 Million ADS Offering; Stock Falls After-Hours
Business Wire
a day ago
Zai Lab Announces Proposed Public Offering of American Depositary Shares
GuruFocus.com
2 days ago
Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability
Zacks
2 days ago
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
Pharmaceutical Technology
3 days ago
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
MT Newswires
3 days ago
Zai Lab's Q3 Loss Narrows, Revenue Rises
Business Wire
3 days ago
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.